Comparison of Two Initial Doses of Growth Hormone Treatment in Children with Growth Hormone Deficiency During the First Year
Led by Northwell Health · Updated on 2026-10-21
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a randomized, open-label study to compare two different starting doses of recombinant human growth hormone rhGH in children aged 5 to 15 years who have growth hormone deficiency. The study aims to evaluate safety, growth rate, and predicted adult height over the first year of treatment to find the optimal initial dose for this condition.
Participants will be randomly assigned to one of two groups one group will receive rhGH at a dose of 0.3 mgkg per week, and the other group will receive 0.2 mgkg per week. Both doses will be given through subcutaneous injections nightly for 12 months. The study will monitor safety and growth outcomes at intervals throughout the year.
During the study, participants will have assessments every 4 months to measure height velocity and predict adult height using bone age. Safety tests will include blood markers such as IGF1, IGFBP3, HbA1c, thyroid hormones, and others at baseline and follow-ups. The total participation spans one year, during which growth and safety parameters will be carefully tracked to understand the effects of the two dosing regimens.
CONDITIONS
Brief Title
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
Research Team
N
Namma Pollack-Schreiber, MD
I
Ishrat Ghani
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Somatropin 0.2 mg/kg/week
Somatropin 0.3 mg/kg/week
What it is
Nightly injections of somatropin (recombinant human growth hormone, rhGH) at a dose of 0.2 mg/kg per week, administered subcutaneously for one year.
Nightly injections of somatropin (rhGH) at a dose of 0.3 mg/kg per week, given subcutaneously for one year.
Role in study
This group receives the lower standard dose of rhGH as one of two randomized treatment arms.
This group receives the higher standard dose of rhGH for comparison in the randomized trial.
Primary use or purpose
Used to promote growth in children diagnosed with growth hormone deficiency, aiming to determine if a lower initial dose supports adequate annual growth velocity.
Used for growth promotion in children with growth hormone deficiency, testing whether a higher initial dose yields better first-year growth outcomes.
How it is given or performed
Administered as a nightly subcutaneous injection by the participant or caregiver.
Given as nightly subcutaneous injections similar to the lower-dose group, with a higher total weekly dose.
Published evidence status
Lower-dose rhGH regimens (around 0.2 mg/kg/week) are well established for stimulating growth in children with growth hormone deficiency, with long-term studies showing improvement in final height outcomes and safety.
Higher-dose rhGH regimens (up to 0.3 mg/kg/week) can produce additional early growth but require careful balance due to potential increased risk of adverse effects. Some studies suggest modest height benefit with similar safety in the first year.
Important limitations
Lower-dose regimens may result in less rapid first-year growth for some children, and may not maximize final height in all subgroups. Individualized dosing is increasingly discussed but not addressed in this protocol.
Starting with a higher rhGH dose can increase costs and may also increase the chance of metabolic or endocrine side effects such as glucose intolerance. Long-term risks and benefits require further study beyond one year.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 5Years - 15Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Signed and dated informed consent form
Willingness to comply with all study procedures and available for the full study duration
Male or female aged 5 to 15 years
In good general health or diagnosed with growth hormone deficiency
Ability to take nightly subcutaneous growth hormone injections
You will not qualify if you...
Growth hormone resistance
Syndromic short stature such as Prader Willi syndrome or Turner syndrome
Active malignancies
Systemic illnesses including heart failure, kidney failure, or liver failure
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 12 months
Participants receive nightly subcutaneous injections of recombinant human growth hormone at one of two doses for 12 months.
Assessments every 4 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
CrescNet Network for Monitoring Growth and Weight Development in Children and Adolescents up to 18 Years
Evaluation of Growth and Tolerance for a New Extensively Hydrolyzed Casein Infant Formula Compared to a Commercially Available Formula
Study to Identify New Genetic Causes of Growth, Puberty, and Sex Development Disorders
Study on How Diet and Nutrition Affect Growth and Development in Children Up to 2 Years Old in Remote and Urban Areas of District Swat, Pakistan
Evaluating Higher Versus Standard Zinc Supplementation to Improve Growth in Extremely Premature Infants
Observational Study on How Iron Deficiency Anemia Affects Neurobehavioral and Physical Development in Children Aged 6 to 24 Months
Study to Improve AI Algorithms for Measuring Length and Weight in Babies from Birth to 6 Months
Comparison of Two Initial Doses of Growth Hormone Treatment in Children with Growth Hormone Deficiency During the First Year
Targeted Fortification of Donor Breast Milk in Preterm Infants to Improve Growth Compared to Standard Fortification
Real-world Study of PEGylated Recombinant Human Growth Hormone for Treating Short Stature in Chinese Children up to 18 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults.
Cesar L Boguszewski, Ludimyla H F Meister, Daniele C T Zaninelli...
Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group.
Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study.
Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study.
Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database.